A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy
A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy
Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN
Study Sponsor, originally HI-Bio, Inc., is now HI-Bio, A Biogen Company.
Key Inclusion Criteria:
Key Exclusion Criteria:
Nový Jicín, Moravian-Silesian Region 741 01, Czechia
Tbilisi, 144, Georgia
Kitakyushu-Shi, Hukuoka 807-8556, Japan
Kurume-Shi, Hukuoka 830-0011, Japan
Ashikaga-Shi, Tochigi 326-0843, Japan
Bunkyō-Ku, Tokyo 113-8431, Japan
Suita-Shi, Ôsaka 565-0871, Japan
Ternopil, Ternopil Oblast 46002, Ukraine